...
首页> 外文期刊>Japan Chemical Daily >AGC Plans to Invest Over 200B Yen in CDMO Operations for Gene & Cell Therapy, More
【24h】

AGC Plans to Invest Over 200B Yen in CDMO Operations for Gene & Cell Therapy, More

机译:AGC在CDMO计划投资200多日元操作基因和细胞治疗,更多

获取原文
获取原文并翻译 | 示例
           

摘要

AGC Inc. (TYO:5201) is looking to invest more than 200 billion yen ($1.7 billion) into CDMO operations by 2025. Plans here are to bolster production sites for biopharmaceuticals – as well as those for gene and cell therapies – across Japan, the U.S. and Europe. By then leveraging operations in these three key regions, the company aims to actively deploy offerings focused on new modalities, facilitating the growth of a strategic business that can support the company as a whole.
机译:AGC Inc .(莫:5201)正寻求投资多2000亿日元(17亿美元)到CDMO在2025年的操作。对生物制药生产基地——这些基因和细胞治疗-日本、美国和欧洲。操作这三个关键地区公司的目标是积极部署产品集中新模式,促进经济增长战略业务能够支持公司作为一个整体。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号